Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits

Publication date: Available online 20 September 2017 Source:Gynecologic Oncology Reports Author(s): Abigail S. Zamorano, Leping Wan, Matthew A. Powell, L. Stewart Massad Our objective was to assess overall survival of cervical cancer patients following prior platinum/bevacizumab chemotherapy, comparing retreatment with platinum/bevacizumab with alternative therapies. A retrospective analysis was performed of women who received platinum/bevacizumab (PB) chemotherapy for cervical cancer at Washington University between July 1, 2005 and December 31, 2015. Wilcoxon rank-sum exact test and Fisher's exact test were used to compare the treatment groups, and Kaplan Meier curves were generated. Cox regression analyses were performed, with treatment free interval and prior therapy response included as covariates. Of 84 patients who received PB chemotherapy, 59 (70%) received no second line chemotherapy, as they did not recur, progressed without further chemotherapy, were lost to follow up, or expired. Of the remaining 25 patients, 9 were retreated with the combination of platinum/bevacizumab (PB), 6 were retreated with a platinum regimen without bevacizumab (P), and 10 were retreated with neither (not-P). The only long-term survivor was in the not-P group and was treated with an immunotherapy agent. Median overall survival of all patients was 7.1months. There was a marginal difference in survival between women in the PB and not-PB groups (11.8 versus 5.7months; HR 3.02, 95% CI, 0.98&n...
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research

Related Links:

Publication date: Available online 7 October 2020Source: Clinical Epidemiology and Global HealthAuthor(s): DrJyoti Singh, DrSulakshana S. Baliga
Source: Clinical Epidemiology and Global Health - Category: Epidemiology Source Type: research
Over the last years, increasing evidence has focused on crucial pathogenetic role of PRL on malignant, premalignant and benign uterine diseases. Studies in animals and humans have documented that PRL receptors (PRL-Rs) are widely expressed on uterine cells and that PRL is directly synthesized by the endometrium under the stimulatory action of progesterone. Uterine PRL secretion is finely modulated by autocrine/paracrine mechanisms which do not depend on the same control factors implied in the regulation of PRL secretion from pituitary. On the other hand, PRL is synthesized also in the myometrium and directly promotes uteri...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Human Papillomavirus (HPV) vaccination among adolescents is an important strategy to prevent cervical and other cancers in adulthood. However, uptake remains far below the Healthy People 2020 targets for the U...
Source: BMC Public Health - Category: Consumer Health News Authors: Tags: Research article Source Type: research
ConclusionWe trained and cross-validated an  RID predictive model with high discriminative ability at both 6 and 12 months after RT. We expect to improve the predictive power of this model by enlarging the number of training datasets.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
In this study, we show that18F-DCFPyl might detect neovasculature in advanced, metastatic differentiated thyroid cancer (DTC). We first stained the preserved lymph node samples of three patients with DTC who had undergone total thyroidectomy and neck dissection for cervical lymph node metastatic disease to identify PSMA expression, with the PSMA antibody (DAKO Monoclonal). Then, we performed18F-DCFPyl imaging in two other advanced DTC patients with elevated serum thyroglobulin (Tg), indicative of residual disease. We compared the findings with contemporaneous FDG PET/CT scan, conventional Imaging (CT,MRI) and whole-body sc...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
mande Jin-Xiong She Molecular biomarkers that can predict survival and therapeutic outcome are still lacking for cervical cancer. Here we measured a panel of 19 serum proteins in sera from 565 patients with stage II or III cervical cancer and identified 10 proteins that have an impact on disease specific survival (DSS) (Hazzard’s ratio; HR = 1.51–2.1). Surprisingly, all ten proteins are implicated in senescence-associated secreted phenotype (SASP), a hallmark of cellular senescence. Machine learning using Ridge regression of these SASP proteins can robustly stratify patients with high SASP, which ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Rita E. Serda Macrophages line the walls of microvasculature, extending processes into the blood flow to capture foreign invaders, including nano-scale materials. Using mesoporous silica nanoparticles (MSNs) as a model nano-scale system, we show the interplay between macrophages and MSNs from initial uptake to intercellular trafficking to neighboring cells along microtubules. The nature of cytoplasmic bridges between cells and their role in the cell-to-cell transfer of nano-scale materials is examined, as is the ability of macrophages to function as carriers of nanomaterials to cancer cells. Both direct administration ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Source: IEEE/ACM Transactions on Computational Biology and Bioinformatics - Category: Bioinformatics Source Type: research
CONCLUSIONS: Epigenetic changes through enzymes like LSD1 may also be of interest for patients with cervical cancer. A combined therapy with other proteins relayed to cervical cancer like GPER might be of interest for future investigations. PMID: 32725356 [PubMed - indexed for MEDLINE]
Source: Clin Med Res - Category: Research Authors: Tags: J Cancer Res Clin Oncol Source Type: research
More News: Alternative and Complementary Therapies | Avastin | Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Clinical Trials | Complementary Medicine | Immunotherapy | OBGYN | Washington University | Women